Haleon PLCHLN
▼ NegativeCapitalrelevance
Analyst downgrade from Buy to Neutral with price target

Rothschild & Co Redburn analyst Edward Lewis downgraded Haleon from Buy to Neutral with a 365 GBp price target. The downgrade comes as Haleon announced a roughly GBP 175 million investment to expand in India, including a new oral health manufacturing facility in Madhya Pradesh and strengthened rural distribution. The investment aims to boost supply capabilities across Asia and increase access to brands like Sensodyne and Parodontax. Haleon is a global consumer healthcare company operating in over 170 markets.
Haleon PLCAnalyst downgrade from Buy to Neutral with price target